Characteristics and potential biomarkers of adult sickle cell patients with chronic pain.
chronic pain
nerve growth factor
opioid
sickle cell patients
substance P
tryptase
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
15
04
2020
revised:
27
05
2020
accepted:
29
05
2020
pubmed:
5
6
2020
medline:
30
7
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
In this study, we investigated the evolution of chronic pain in sickle cell patients (SCD) as an age-dependent phenomenon and studied the frequency of vaso-occlusive episode frequency, opioid use, quantitative sensory testing (QST), and biomarkers of chronic pain (CP). We undertook a cross-sectional study of the evolution of CP in SCD. A total of 72 subjects (age 15-66) were enrolled. VOE frequency, presence of CP hydroxyurea (HU) therapy, opioid use, and laboratory parameters were collected. QST was performed, and plasma tryptase, substance P, and NGF (Nerve Growth Factor) levels were assayed. There was an age-dependent increase in frequency of CP, VOEs, opioid use, and Von Frey monofilament values. CP patients had significantly higher opioid use (daily morphine equivalents) (52.8 mg vs 6.94 mg, P = .009), suggesting a correlation between opioid use and hyperalgesia. NGF levels were also significantly higher (P = .051). Our results confirm previous observations of an age-dependent increase in the proportion of patients with CP and support the contributing role of mast cell activation and neurogenic inflammation. This is the first study of NGF as a possible biomarker of CP in SCD. If confirmed, this could provide a diagnostic marker and therapeutic target for CP in SCD.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
419-425Subventions
Organisme : NIMHD NIH HHS
ID : P20 MD003383
Pays : United States
Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Brandow AM, Zappia KJ, Stucky CL. Sickle cell disease: a natural model of acute and chronic pain. Pain. 2017;158(Suppl 1):S79-S84.
Keikhaei B, Mohseni AR, Norouzirad R, et al. Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. Eur Cytokine Netw. 2013;24(1):45-52.
Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94-101.
Stoicea N, Russell D, Weidner G, et al. Opioid-induced hyperalgesia in chronic pain patients and the mitigating effects of gabapentin. Frontiers Pharmacol. 2015;6:104.
Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018-2031.
Vincent L, Vang D, Nguyen J, et al. Mast cell activation contributes to sickle cell pathobiology and pain in mice. Blood. 2013;122(11):1853-1862.
Kuei N, Patel N, Xu H, et al. Characteristics and potential biomarkers for chronic pain in patients with sickle cell disease. Blood. 2015;126(23):986.
Denk F, Bennett DL, McMahon SB. Nerve growth factor and pain mechanisms. Annu Rev Neurosci. 2017;40:307-325.
Backonja M-M, Walk D, Edwards RR, et al. Quantitative sensory testing in measurement of neuropathic pain phenomena and other sensory abnormalities. Clinical J Pain. 2009;25(7):641-647.
Darbari DS, Brandow AM. Pain-measurement tools in sickle cell disease: where are we now? Hematology. 2017;2017(1):534-541.
Michaels LA, Ohene-Frempong K, Zhao H, Douglas SD. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood. 1998;92(9):3148-3151.
Douglas SD. Elevated plasma substance P in sickle cell disease and vaso-occlusive crisis. Med Hypotheses. 2008;70(6):1229.
Brandow AM, Wandersee NJ, Dasgupta M, et al. Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use. Br J Haematol. 2016;175(2):237-245.
Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006;27(2):85-91.
Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs. 2008;22(6):349-359.
Campbell CM, Carroll CP, Kiley K, et al. Quantitative sensory testing and pain-evoked cytokine reactivity: comparison of patients with sickle cell disease to healthy matched controls. Pain. 2016;157(4):949-956.
Ezenwa MO, Molokie RE, Wang ZJ, et al. Safety and utility of quantitative sensory testing among adults with sickle cell disease: indicators of neuropathic pain? Pain Practice. 2016;16(3):282-293.
Campbell CM, Moscou-Jackson G, Carroll CP, et al. An evaluation of central sensitization in patients with sickle cell disease. J Pain. 2016;17(5):617-627.
Meiler SE, Wells LG, Bowman L, et al. Pressure pain threshold and pain diary data in patients with sickle cell disease. Blood. 2012;120:1007.
Brandow AM, Kattappuram R, Stucky CL, Hillery CA, Panepinto JA. Patients with sickle cell disease have increased sensitivity to cold and heat stimuli, 2. Blood. 2011;118:2116.
Carroll CP, Lanzkron S, Haywood C, et al. Chronic opioid therapy and central sensitization in sickle cell disease. Am J Prev Med. 2016;51(1):S69-S77.
Mager A, Pelot K, Koch K, et al. Opioid management strategy decreases admissions in high-utilizing adults with sickle cell disease. J Opioid Manag. 2017;13(3):143-156.
Control CfD, Prevention. Annual surveillance report of drug-related risks and outcomes-United States, 2017. Surveillance Special Report. 2017;1(10):1-83.